Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Financial Tear Sheet Corporate Profile PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expert-based contract research, consulting, medical communications, and technology solutions to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Corporate Structure The Company is managed through three business segments: Clinical Research Services (CRS), PAREXEL Consulting Services, and PAREXEL Informatics (PI). CRS constitutes the Company's core business and includes all phases of clinical research from “first-in-man” trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. PAREXEL Consulting Services provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice (“GMP”) compliance consulting. In addition, PC provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PC consultants also identify alternatives and propose solutions to address clients’ product development, registration, and commercialization issues. PAREXEL Informatics provides information technology solutions designed to improve clients’ product development processes. PI’s portfolio of products and services includes ClinPhone RTSM, medical imaging services, RIM, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite. Page 1/3 Stock Quote Stock Chart PRXL (Common Stock) Exchange NASDAQ (US Dollar) Price $64.54 Change (%) 0.83 (1.27%) Volume 797,829 52 Week Low $51.16 Market Cap $3,330,901,221 Rolling EPS 2.82 PE Ratio 23.1617 Shares Outstanding 50,954,585 Data provided by Nasdaq. Minimum 15 minutes delayed. Data as of 05/03/17 4:00 p.m. ET Recent Press Releases Recent Events May 03, 2017 PAREXEL International Reports Third Quarter Fiscal Year 2017 Results Thursday, June 30, 2016 9:00 a.m. ET PAREXEL International Investor Day 2016 April 17, 2017 Parexel International Announces Date of Third Quarter Fiscal Year 2017 Earnings Release and Conference Call April 03, 2017 PAREXEL Ranked a Top CRO in CenterWatch Global Investigative Site Relationship Survey Thursday, May 4, 2017 10:00 a.m. ET Q3 2017 PAREXEL International Earnings Conference Call Page 2/3 SEC Filings Contact Information Filing Date Form 03/06/17 4 03/02/17 8-K 02/28/17 8-K 02/23/17 8-K Ronald Aldridge Sr. Director, Investor Relations PAREXEL International Corporation Phone: +1-781-434-4753 Email: [email protected] Board of Directors A. Dana Callow, Jr. Managing General Partner Boston Millennia Partners Patrick J. Fortune, Ph.D. Vice President Market Sectors Partners HealthCare Maykin Ho, Ph.D. Managing Partner Viridian Global Eduard E. Holdener, M.D. Chairman and Chief Executive Officer NovImmune S.A. Emeritus Head of Global Pharmaceutical Development F. Hoffman-La Roche, Ltd. Christopher J. Lindop Chief Financial Officer Quotient Limited Richard L. Love Managing Partner Translational Accelerator, LLC (TRAC) Josef H. von Rickenbach Chairman of the Board and Chief Executive Officer PAREXEL International Corporation Ellen M. Zane CEO Emeritus Vice Chair, Board of Trustees Tufts Medical Center Page 3/3